WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen, Inc. (IMGN), a biotechnology company that develops anticancer therapeutics, today announced that investors, journalists and the general public are invited to listen to a live webcast of the Company’s analyst and investor community meeting on April 12, 2013. The webcast will begin at 8:30 a.m. ET and may be accessed through the Investor Information section of the Company’s website, www.immunogen.com. The meeting is expected to last approximately three hours, including a short break, and to contain updated information related to the status of the Company’s IMGN901 NORTH Phase II trial and its IMGN853 abstract submitted to ASCO. An archive of the webcast will be available on the Company’s website through April 26, 2013.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's Targeted Antibody Payload (TAP) technology uses a tumor-targeting monoclonal antibody to deliver one of ImmunoGen's highly potent cancer-cell killing agents specifically to tumor cells. Ten TAP compounds are now in the clinic, of which three are wholly owned by the Company. The most advanced compound using ImmunoGen's TAP technology, KADCYLA (formerly T-DM1), has been approved for marketing in the US and is undergoing regulatory review in Europe and Japan; it is being commercialized in the US by Genentech, a member of the Roche Group. More information about ImmunoGen can be found at www.immunogen.com.
- Investment & Company Information
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and Corporate Communications
The Yates Network
Barbara Yates, 781-258-6153